» Authors » Ligia C Pierrotti

Ligia C Pierrotti

Explore the profile of Ligia C Pierrotti including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 324
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Freire M, Camargo C, Bubach L, Yamada A, Spadao F, Lopes C, et al.
Transpl Infect Dis . 2024 Dec; 27(1):e14414. PMID: 39632684
Background: Infections by carbapenem-resistant Pseudomonas aeruginosa (CRPA) have been associated with high morbidity and mortality among solid organ recipients. Objectives: To delineate the epidemiological and molecular characteristics of a recurrent...
2.
Coussement J, Bansal S, Scemla A, Svensson M, Barcan L, Smibert O, et al.
Transpl Infect Dis . 2024 Aug; 26(6):e14362. PMID: 39185755
Background: Despite the burden of pyelonephritis after kidney transplantation, there is no consensus on initial empirical antibiotic management. Methods: We surveyed clinicians throughout the world on their practice and opinions...
3.
Pierrotti L, Clemente W
Transplantation . 2023 Apr; 107(8):1669-1670. PMID: 37046377
No abstract available.
4.
Freire M, de Oliveira Garcia D, Lima S, Pea C, Junior J, Spadao F, et al.
Infection . 2022 May; 50(6):1525-1533. PMID: 35534755
Background: Infection with carbapenem-resistant Enterobacterales (CRE) is associated with a high mortality rate in kidney transplant recipients, and colonization with CRE is one of the major risk factors for CRE...
5.
Corral M, Goncalves A, Costa I, Abdala E, Pierrotti L, Chieffi P, et al.
Parasite Immunol . 2022 Apr; 44(7):e12920. PMID: 35430739
Strongyloidiasis is a chronic and asymptomatic infection in immunocompetent patients. Immunocompromised patients, such as organ transplant candidates, can develop severe forms of this disease, and the best way to prevent...
6.
Moura M, Boszczowski I, Blaque M, Mussarelli R, Fossaluza V, Pierrotti L, et al.
Emerg Infect Dis . 2021 Dec; 28(1):180-187. PMID: 34932455
Although restricting over-the-counter (OTC) antimicrobial drug sales is recommended globally, no data track its effect on antimicrobial resistance (AMR) in bacteria. We evaluated the effect of a national policy restricting...
7.
Rodrigues C, Freitas-Santos R, Levi J, Senerchia A, Lopes A, Santos S, et al.
Int J Antimicrob Agents . 2021 Aug; 58(5):106428. PMID: 34454044
Background: Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-2 in some in vitro studies. This randomised, double-blinded, placebo controlled clinical trial evaluated the efficacy of hydroxychloroquine plus azithromycin...
8.
Giannella M, Pierrotti L, Helantera I, Manuel O
Transpl Int . 2021 Aug; 34(10):1776-1788. PMID: 34450686
In response to the COVID-19 pandemic, SARS-CoV-2 vaccines have been developed at an unparalleled speed, with 14 SARS-CoV-2 vaccines currently authorized. Solid-organ transplant (SOT) recipients are at risk for developing...
9.
Freire M, Carvalho L, Reusing Jr J, Spadao F, Lopes M, Nahas W, et al.
Infect Dis (Lond) . 2021 Feb; 53(6):430-439. PMID: 33612056
Background: Kidney transplant recipients are a risk group for carbapenem-resistant Enterobacteriaceae infection. Objectives: This study aimed to identify risk factors for CRE acquisition and infection among kidney transplant recipients. Methods:...
10.
Pierrotti L, Perez-Nadales E, Fernandez-Ruiz M, Gutierrez-Gutierrez B, Tan B, Carratala J, et al.
Transpl Infect Dis . 2020 Nov; 23(3):e13520. PMID: 33222379
Background: Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant...